Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Medicus Pharma Ltd. (MDCX) ownership amendment reports that Dr. Kenneth Melani may be deemed the beneficial owner of 3,248,741 common shares, or 3.6%. Velocity Fund Partners, LP directly owns 2,839,330 shares, or 3.2%, while Melani directly owns 409,411 shares. Melani disclaims beneficial ownership of the fund’s shares except to the extent of his direct ownership. The reported percentages are based on 89,762,721 common shares outstanding as of September 10, 2026.
Key Figures
Beneficially owned shares:3,248,741 common sharesBeneficial ownership percentage:3.6%Directly owned shares:409,411 common shares+3 more
6 metrics
Beneficially owned shares3,248,741 common sharesDr. Kenneth Melani; includes shares held by Velocity Fund Partners, LP
Directly owned shares409,411 common sharesDr. Kenneth Melani
Directly owned shares2,839,330 common sharesVelocity Fund Partners, LP
Ownership percentage3.2%Velocity Fund Partners, LP
Common shares outstanding89,762,721 sharesAs of September 10, 2026; denominator used for the reported percentages
Key Terms
beneficial owner, Sole Voting Power, Sole Dispositive Power
3 terms
beneficial ownerregulatory
"may be deemed the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Sole Voting Powerregulatory
"Sole Voting Power 3,248,741.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Powerregulatory
"Sole Dispositive Power 3,248,741.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many MDCX shares does Dr. Kenneth Melani report as beneficially owned?
Dr. Kenneth Melani may be deemed the beneficial owner of 3,248,741 common shares, or 3.6%. This includes 409,411 shares he directly owns and 2,839,330 shares held by Velocity Fund Partners, LP. He disclaims beneficial ownership of the fund’s shares except to the extent of his direct ownership.
What share count was used to calculate the MDCX ownership percentages?
The percentages use 89,762,721 common shares reported outstanding as of September 10, 2026. The cited share count was reflected in a Schedule 13D filed by the company’s Executive Chairman and CEO.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Medicus Pharma Ltd.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
58471K301
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
58471K301
1
Names of Reporting Persons
Melani Kenneth R.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,248,741.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,248,741.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,248,741.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Includes: (i) 409,411 common shares held by Dr. Kenneth Melani and (ii) 2,839,330 common shares held by Velocity Fund Partners, LP and entity controlled by Dr. Kenneth Melani. Dr. Kenneth Melani may be deemed the beneficial owner of securities held by Velocity Fund Partners, LP. Dr. Kenneth Melani disclaims beneficial ownership of such securities except to the extent of his direct ownership.
SCHEDULE 13G
CUSIP Number(s):
58471K301
1
Names of Reporting Persons
VELOCITY FUND PARTNERS, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,839,330.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,839,330.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,839,330.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Medicus Pharma Ltd.
(b)
Address of issuer's principal executive offices:
300 CONSHOHOCKEN STATE RD., SUITE 200, W. CONSHOHOCKEN, PENNSYLVANIA, 19428.
Item 2.
(a)
Name of person filing:
This statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"):
(i) Dr. Kenneth Melani; and
(ii) Velocity Fund Partners, LP
(b)
Address or principal business office or, if none, residence:
The principal business address of each of the Reporting Persons is as follows:
1100 Stonegate Manor
Cheswick, PA 15024
(c)
Citizenship:
See Row (4) of each Reporting Person's cover page.
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP No.:
58471K301
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Dr. Kenneth Melani directly owns 409,411 common shares of Medicus Pharma Ltd. (the "Company"). Velocity Fund Partners, LP an entity controlled by Dr. Kenneth Melani, directly owns 2,839,330 common shares. Dr. Kenneth Melani may be deemed the beneficial owner of the securities held by Velocity Fund Partners, LP. Dr. Kenneth Melani disclaims beneficial ownership of such securities except to the extent of this direct ownership.
(b)
Percent of class:
See Row (11) of each Reporting Person's cover page. The percentages used herein are calculated based upon an aggregate of 89,762,721common shares reported to be outstanding as of September 10, 2026, as reflected in the Report on Schedule 13D filed by the Company's Executive Chairman & CEO on September 14, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row (5) of each Reporting Person's cover Page
(ii) Shared power to vote or to direct the vote:
See Row (6) of each Reporting Person's cover Page
(iii) Sole power to dispose or to direct the disposition of:
See Row (7) of each Reporting Person's cover Page
(iv) Shared power to dispose or to direct the disposition of:
See Row (8) of each Reporting Person's cover Page
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Melani Kenneth R.
Signature:
/s/ Kenneth Melani
Name/Title:
Dr. Kenneth Melani
Date:
10/16/2026
VELOCITY FUND PARTNERS, LP
Signature:
/s/ Kenneth Melani
Name/Title:
Dr. Kenneth Melani, General Partner
Date:
10/16/2026
Exhibit Information
Exhibit 99.1: Joint Filing Agreement (previously filed as Exhibit 99.1 to the Schedule 13G filed on February 13, 2025, and incorporated herein by reference).
